|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The granulocyte-colony stimulating factor (G-CSF) biosimilar filgrastim (Nivestim™) reduces the duration and severity of neutropenia and the frequency of occurrence of febrile neutropenia (FN).
|
30410313 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with G-CSF could eventually be stopped, and the neutropenia, ultimately transient in nature, completely resolved.
|
30633375 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consequently, G-CSF has been used to support patients undergoing chemotherapy who would otherwise require dose reduction due to neutropenia.
|
29968171 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy delay due to neutropenia was higher in patients who received granulocyte-colony stimulating factor on day 1.
|
31042138 |
2020 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with WHIM syndrome are often treated with granulocyte colony-stimulating factor (G-CSF), which can increase neutrophil counts but does not affect cytopenias other than neutropenia.
|
30625055 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) has been used in the clinic for more than 2 decades to treat congenital and acquired neutropenias and to reduce febrile neutropenia before or during courses of intensive cytoreductive therapy.
|
20237318 |
2010 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Filgrastim, a recombinant human granulocyte-colony stimulating factor, is widely used to treat congenital and acquired neutropenia.
|
30280277 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
ALL chemotherapy is associated with numerous side effects including neutropenia that is routinely prevented by the administration of growth factors such as granulocyte colony-stimulating factor (G-CSF).
|
30034479 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia.
|
30727980 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that G-CSF can sometimes be safely used to support the maintenance of normal neutrophil counts and clozapine use after neutropenia.
|
28817489 |
2017 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer Patients.
|
29392707 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent reports suggest that a beneficial effect may be observed in the administration of hematopoietic growth factors (G-CSF, GM-CSF) for patients with DC and neutropenia.
|
9773234 |
1998 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated a retrospective cohort of 228 adult lung transplant recipients between 2008 and 2013 to assess the association of neutropenia and granulocyte colony-stimulating factor (GCSF) treatment with outcomes.
|
31452317 |
2020 |
|
Neutropenia
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Weekly infusions of CSL324 (≤10 mg/kg) for 3 wk completely neutralized G-CSF-mediated pSTAT3 phosphorylation without neutropenia.
|
28515226 |
2017 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neutropenia was managed with dose delays and granulocyte colony-stimulating factor; no dose reductions or discontinuations were required.
|
29859255 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synthesis and characterization of heparosan-granulocyte-colony stimulating factor conjugates: a natural sugar-based drug delivery system to treat neutropenia.
|
28973394 |
2017 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pegfilgrastim or Filgrastim injection can lead to a reduction in febrile neutropenia and severe neutropenia in patients
|
29072395 |
2017 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
G-CSF should not routinely be used for infants with neutropenia.
|
27649291 |
2017 |
|
Neutropenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, intramuscular administration of lentivirus encoding G-CSF provided sustained therapeutic levels of neutrophils, suggesting this approach may be applied for long-term treatment of patients with cyclic and other neutropenias.
|
12750178 |
2003 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The addition of G-CSF to attenuate neutropenia did not improve tolerability.
|
30128950 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Current guidelines (GL) recommend neutropenia prophylaxis with G-CSF after chemotherapy (CTX) for patients with high (≥ 20%), or, if additional risk factors are present, intermediate (≥ 10-20%) risk of febrile neutropenia.
|
30374765 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein commonly used in the field of medicine to treat neutropenia.
|
30497339 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Many of the neutropenia disorders can be treated with G-CSF (filgrastim) to increase the neutrophil count, thereby reducing infection morbidity and mortality.
|
17584878 |
2007 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study shows the increase or decrease in monocyte count is a significant potential indicator to predict the occurrence of neutropenia, and it is also a predictor to guide the next monitoring time of neutrophil count and the treatment of granulocyte-colony stimulating factor.
|
30249869 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ghrelin therapy was able to enhance and sustain the increases in serum on day 15, probably contributed by spleen and ileum, suggesting the correlation between G-CSF and KC increases and the neutropenia mitigation.
|
29632660 |
2018 |